Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
It will be a pilot, 2 year, prospective, randomized, double-blind, placebo-controlled (for
pamidronate) study. All patients with AS will receive treatment with TNF inhibitor, while
randomization will be performed for pamidronate versus placebo group. Primary outcome will be
the rate of radiographic progression of AS, calculated after 24 months of combined treatment.